Gaëlle Asset

1.3k total citations · 1 hit paper
24 papers, 717 citations indexed

About

Gaëlle Asset is a scholar working on Hematology, Surgery and Genetics. According to data from OpenAlex, Gaëlle Asset has authored 24 papers receiving a total of 717 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 10 papers in Surgery and 7 papers in Genetics. Recurrent topics in Gaëlle Asset's work include Multiple Myeloma Research and Treatments (12 papers), Cholesterol and Lipid Metabolism (5 papers) and Peptidase Inhibition and Analysis (5 papers). Gaëlle Asset is often cited by papers focused on Multiple Myeloma Research and Treatments (12 papers), Cholesterol and Lipid Metabolism (5 papers) and Peptidase Inhibition and Analysis (5 papers). Gaëlle Asset collaborates with scholars based in France, United States and United Kingdom. Gaëlle Asset's co-authors include Eli M. Roth, Evan A. Stein, James M. McKenney, Corinne Hanotin, Eric Baugé, Jean Dallongeville, Jean‐Charles Fruchart, Robert L. Wolff, Marie‐Laure Risse and Philippe Moreau and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of Clinical Oncology.

In The Last Decade

Gaëlle Asset

24 papers receiving 690 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia

2012 383 citations Eli M. Roth, James M. McKenney et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Gaëlle Asset

Since Specialization

Citations

This map shows the geographic impact of Gaëlle Asset's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gaëlle Asset with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gaëlle Asset more than expected).

Fields of papers citing papers by Gaëlle Asset

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gaëlle Asset. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gaëlle Asset. The network helps show where Gaëlle Asset may publish in the future.

Co-authorship network of co-authors of Gaëlle Asset

This figure shows the co-authorship network connecting the top 25 collaborators of Gaëlle Asset. A scholar is included among the top collaborators of Gaëlle Asset based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gaëlle Asset. Gaëlle Asset is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma 2022 ·Blood Advances ·Thomas G. Martin, Joseph Mıkhael, Roman Hájek, Kihyun Kım, Kenshi Suzuki, Cyrille Hulin, Mamta Garg, Hang Quach, Hanlon Sia, (unknown), Т. С. Константинова, Marie‐Laure Risse, Gaëlle Asset, Sandrine Macé, Helgi van de Velde, Philippe Moreau	6
2	Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysis 2022 ·European Journal Of Haematology ·Ivan Špıčka, Philippe Moreau, Thomas G. Martin, Thierry Façon, Gracia Martínez, Albert Oriol, Youngil Koh, Andrew Lim, Gábor Mikala, Laura Rosiñol, Münci Yağcı, Michèle Cavo, Marie‐Laure Risse, Gaëlle Asset, Sandrine Macé, Helgi van de Velde, Kwee Yong	13
3	Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis. 2021 ·Journal of Clinical Oncology ·Thierry Façon, Philippe Moreau, Thomas Martin, Ivan Špıčka, Albert Oriol, Youngil Koh, Andrew Lim, Gábor Mikala, Laura Rosiñol, Münci Yağcı, Michèle Cavo, Kwee Yong, Marie‐Laure Risse, Gaëlle Asset, (unknown), Gracia Martínez	7
4	MM-092: Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Elderly Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis 2021 ·Clinical Lymphoma Myeloma & Leukemia ·Thierry Façon, Philippe Moreau, Thomas G. Martin, Ivan Špıčka, Albert Oriol, Youngil Koh, Andrew Lim, Gábor Mikala, Laura Rosiñol, Münci Yağcı, Michèle Cavo, Kwee Yong, Marie‐Laure Risse, Gaëlle Asset, (unknown), Gracia Martínez	1
5	Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis. 2021 ·Journal of Clinical Oncology ·Ivan Špıčka, Philippe Moreau, (unknown), Thierry Façon, Gracia Martínez, Albert Oriol, Youngil Koh, Andrew Lim, Gábor Mikala, Laura Rosiñol, Münci Yağcı, Michèle Cavo, Marie‐Laure Risse, Gaëlle Asset, Sandrine Macé, Helgi van de Velde, Kwee Yong	8
6	Depth of Response and Response Kinetics of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Interim Analysis 2020 ·Blood ·Thomas G. Martin, Joseph Mıkhael, Roman Hájek, Kihyun Kım, Kenshi Suzuki, Cyrille Hulin, Mamta Garg, Hang Quach, Hanlon Sia, (unknown), Т. С. Константинова, Marie‐Laure Risse, Gaëlle Asset, Sandrine Macé, Helgi van de Velde, Philippe Moreau	12
7	ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY 2020 ·Hematology Transfusion and Cell Therapy ·Ângelo Maiolino, Philippe Moreau, Meletios Α. Dimopoulos, Joseph Mıkhael, (unknown), Marcelo Capra, Thierry Façon, Roman Hájek, (unknown), Marie‐Laure Risse, Gaëlle Asset, Sandrine Macé, Thomas G Martin	23
8	Isatuximab plus carfilzomib and dexamethasone vs. carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (ikema): interim analysis of a phase 3, randomized, open-label study 2020 ·Hematology Transfusion and Cell Therapy ·Mehmet Turgut, Philippe Moreau, Meletios Α. Dimopoulos, Joseph Mıkhael, Kwee Yong, Marcelo Capra, Thierry Façon, Roman Hájek, (unknown), Marie‐Laure Risse, Gaëlle Asset, Sandrine Macé, Thomas G Martin	6
9	Phase III (IKEMA) study design: Isatuximab plus carfilzomib and dexamethasone (Kd) vs Kd in patients with relapsed/refractory multiple myeloma (RRMM). 2018 ·Journal of Clinical Oncology ·Thomas G. Martin, Meletios Α. Dimopoulos, Kwee Yong, Joseph Mıkhael, Marie‐Laure Risse, Gaëlle Asset, Philippe Moreau	2
10	Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years 2017 ·Journal of clinical lipidology ·Michel Farnier, Helen M. Colhoun, William J. Sasiela, Jay M. Edelberg, Gaëlle Asset, Jennifer G. Robinson	23
11	Treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in six ODYSSEY phase 3 clinical studies with treatment duration of 52 – 104 weeks 2016 ·Atherosclerosis ·(unknown), Helen M. Colhoun, William J. Sasiela, Jay M. Edelberg, Gaëlle Asset, J Robinson	1
12	Abstract 17086: Alirocumab LDL-C-Lowering Efficacy in Patients With Moderate CKD 2015 ·Circulation ·Peter P. Tóth, Christopher P. Cannon, John J.P. Kastelein, Helen M. Colhoun, Andrew Koren, Michael J. Louie, Gaëlle Asset, Daniel J. Rader	2
13	THE EFFECTS OF CO-ADMINISTERING A MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 SERINE PROTEASE, REGN727/SAR236553, WITH 10 AND 80 MG ATORVASTATIN COMPARED TO 80 MG ATORVASTATIN ALONE IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (NCT: 01288469) 2012 ·Journal of the American College of Cardiology ·Eli M. Roth, James McKenney, Corinne Hanotin, Gaëlle Asset, Evan A. Stein	1
14	Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia breakdown → 2012 ·New England Journal of Medicine ·Eli M. Roth, James M. McKenney, Corinne Hanotin, Gaëlle Asset, Evan A. Stein	383
15	Effects of dietary maritime pine seed oil on lipoprotein metabolism and atherosclerosis development in mice expressing human apolipoprotein B 2001 ·European Journal of Nutrition ·Gaëlle Asset, Eric Baugé, Robert L. Wolff, Jean‐Charles Fruchart, Jean Dallongeville	19
16	Lack of Triglyceride-Lowering Properties of Fish Oil in Apolipoprotein E–Deficient Mice 2001 ·Arteriosclerosis Thrombosis and Vascular Biology ·Gaëlle Asset, Eric Baugé, Jean‐Charles Fruchart, Jean Dallongeville	28
17	Pinus pinaster Oil Affects Lipoprotein Metabolism in Apolipoprotein E-Deficient Mice 1999 ·Journal of Nutrition ·Gaëlle Asset, Eric Baugé, Robert L. Wolff, J C Fruchart, Jean Dallongeville	28
18	Effects of Pinus pinaster and Pinus koraiensis seed oil supplementation on lipoprotein metabolism in the rat 1999 ·Lipids ·Gaëlle Asset, Bart Staels, Robert L. Wolff, Eric Baugé, (unknown), Jean‐Charles Fruchart, Jean Dallongeville	76
19	91 Δ5 olefinic acids extracted from pine tree seeds decrease serum triglyceride levels in rats 1997 ·Atherosclerosis ·Gaëlle Asset, Robert L. Wolff, Eric Baugé, J.C. Fruchart, Jean Dallongeville	4
20	1.P.95 Effects of Δ5-olefinic acids from Pinus pinaster seed oil on lipoprotein metabolism in apoE deficient mice 1997 ·Atherosclerosis ·Gaëlle Asset, Eric Baugé, (unknown), J.C. Fruchart, Jean Dallongeville	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact